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Immunohistochemistry (IHC) has been broadly accepted 
as a companion diagnostic method to assist clinicians in 
the prescription of targeted therapies. However, it was 
recently observed that the quality of the biomarker study 
is highly dependent on quality of the tissue. Th   e quality of 
the tissue is dramatically aﬀ   ected by pre-analytic 
variables. Th   ousands of uncontrolled variables that aﬀ  ect 
every tissue specimen could alter the results of com-
panion diagnostic testing. Some common examples 
include cold ischemic time, intraoperative hypoxia, 
section thickness, type of ﬁ  xative, processor protocols, 
and scores of other subtle and not so subtle variables. 
Although it is impossible to control for all pre-analytic 
variables, eﬀ  orts to characterize their eﬀ  ects are under 
way.
In the previous issue of Breast Cancer Research, Pinhel 
and colleagues [1] examined the eﬀ  ects of time to ﬁ  xation 
by the measurement of protein expression of traditional 
breast cancer biomarkers in a timed series of core needle 
biopsies and the conventional resection specimens. Th  e 
authors compared the expression of estrogen receptor 
(ER), Her2, progesterone receptor (PgR), ki-67, p-Akt, 
and p-Erk in each set and used conventional IHC with 
semi-quantitative readouts and found no signiﬁ  cant 
diﬀ  erence between the expression of ER, Her2, PgR, and 
ki-67 in the core needle specimens with a median time 
diﬀ  erence of 30 minutes. Comparison with tumor resec-
tion samples from the same patient also showed no 
signiﬁ  cant diﬀ  erence except that a lower ER value was 
seen in the conventional resection compared with the 
biopsy. Th  ese  ﬁ  ndings suggest that if epitope degradation 
occurs during the ischemic time prior to ﬁ  xation,  its 
impact may be limited to borderline cases.
Th   e impact for phospho-epitopes is not so subtle. Here, 
Pinhel and colleagues show a dramatic loss of antigenicity 
for both p-Akt and p-Erk1/2 when comparing the cores 
with conventional resections. Although these markers 
are not routinely used in current diagnostic testing, their 
potential for sensing pathway activation has made them 
extremely popular candidate markers for companion 
diagnostics for kinase inhibitors [2]. Th   e work of Pinhel 
and colleagues shows signiﬁ   cantly lower levels of the 
phospho-epitopes in tumor resection samples with 
longer time to ﬁ  xation. Th   is work suggests that the timing 
and tissue handling are critical for biomarker assessment 
of phospho-proteins in clinical specimens. Since delayed 
time to ﬁ  xation can alter the phosphorylation status in 
resection specimens, use of these epitopes in companion 
diagnostic tests will likely have to be limited to core 
needle biopsies.
Th   e work of Pinhel and colleagues validates data seen 
in other studies that have shown the decrease in 
phospho-protein biomarker expression as a function of 
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© 2010 BioMed Central Ltdtime to ﬁ  xation [3-5]. Work in our lab has also quantiﬁ  ed 
this loss for these and other phospho-epitopes while 
show  ing less change in the non-phospho-sensitive 
epitopes of the same proteins (Yalai Bai and colleagues, 
Depart  ment of Pathology, Yale University School of 
Medicine, New Haven, CT, USA, manuscript submitted). 
Th  us, although phospho-proteins are a tempting target, 
they present unique challenges. Most likely, this is 
explained by the fact that phospho-epitopes are highly 
sensitive to phospha  tases. In fact, it is the transient 
balance between kinases and phosphatases that is critical 
in cell proliferation, cell migration, and other pathways in 
tumor progression [6]. Most likely, the loss of the 
phospho-epitopes is due to the unregulated phosphatase 
activity seen in ischemic conditions or early-stage tissue 
degradation that occurs prior to ﬁ  xation.
Can anything be done to address this issue of pre-
analytic variability? Eﬀ  orts have been made to standard-
ize tissue management in the American Society of 
Clinical Oncology/College of American Pathologists 
guide  lines for Her2 [7] and for ER and PgR [8]. Th  e  guide-
lines stipulate a maximum of 1 hour between resection 
and ﬁ   xation and a minimum of 6 hours in ﬁ  xative. 
Clinical trial groups have also set guide  lines for specimen 
handling [9]. However, the concept of biospecimen 
science is still relatively new. Historically, work charac-
terizing time to ﬁ  xation and other pre-analytic variables 
was not recognized as important and was diﬃ   cult  to 
publish. As a result, the issued guidelines are based on a 
very limited body of literature [10-12]. Th  e paper of 
Pinhel and colleagues and similar studies are welcome 
additions to the literature. No doubt, there will soon be 
others since the National Institutes of Health has recently 
established the Oﬃ   ce of Biorepositories and Biospecimen 
Research and has funded a series of studies on bio-
specimen science. Th  e work of the funded investigators 
and works like this article by Pinhel and colleagues are 
likely to be cited as key evidence to form the basis of 
future guidelines for companion diagnostic tests.
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